Hematology

Latest News

Regarding survival, outcomes were similar to those seen in clinical trials of ruxolitinib for myelofibrosis. | Image credit: fotogurmespb - stock.adobe.com
Ruxolitinib Shows Sustained Clinical, QOL Benefits in Real-World Data

July 18th 2025

The JAKoMo study highlights ruxolitinib's long-term efficacy and safety in myelofibrosis, showing improved quality of life (QOL) and fewer adverse events in the real-world setting.

refractory mantle cell lymphoma | Image: Kite
After CAR T in Mantle Cell Lymphoma, Choices and a Robust Pipeline

July 17th 2025

DLBCL | Image: Atlas of Haematological Cytology
Lack of CD20 Expression Worsens Outcomes for Bispecifics in R/R DLBCL

July 16th 2025

There was significant variability in test frequency and detection rates among patients with AML and MDS. | Image credit: Saiful52-stock.adobe.com
Gaps in Molecular Testing Rates, Targeted Treatment Persist in MDS, AML

July 11th 2025

The findings have potential implications for treatment selection in CLL/SLL, particularly in patients at elevated risk for infectious complications. | Image credit: Eleni - stock.adobe.com
Higher Infection Risk With Venetoclax-Obinutuzumab vs Zanubrutinib in CLL/SLL

July 7th 2025

Expanding Horizons: The Present and Future of Bispecific Antibodies Across Oncology

Experts explore the latest bispecific antibody approvals and clinical applications, discuss barriers in community oncology, address management of cytokine release syndrome, and consider how these therapies can expand patient access to care.

AJMC Peer Exchange logo

More News

Quality of life in patients with hemophilia A or B benefits from the use of concizumab | image credit: Patrick Daxenbichler - stock.adobe.com
August 18th 2024

Patient-Reported Outcomes Favor Concizumab Prophylaxis in Hemophilia A or B

Connor Iapoce
Analysis of the phase 3 explorer7 (NCT04083781) study indicates a preference for concizumab prophylaxis over no prophylaxis in patients with hemophilia A or B with inhibitors.
AML cells | image credit: LASZLO - stock.adobe.com
August 17th 2024

AML Treatment Has Shifted Toward More Personalized Approach

AJMC Contributor
Recent years have brought a more targeted approach to treating acute myeloid leukemia (AML) based on accumulating knowledge about the genetic makeup of the heterogenous disease.
Cytokine release concept | image credit: Bijac - stock.adobe.com
August 16th 2024

Cytokine Release Syndrome in CAR T-Cell Therapy: A Common Yet Controllable Complication in DLBCL

Kimberly Rath, PharmD
CAR T-cell therapy results in a high incidence of cytokine release syndrome, but it is manageable in most cases.
Maria Amaya, MD, PhD
August 16th 2024

Real-World Outcomes Not Always Reflected in Clinical Trials: Dr Maria Amaya

Kyle Munz
Maria Amaya, MD, PhD, University of Colorado School of Medicine, explores discrepancies between real-world data and clinical trial outcomes, as well as her experience ensuring the reliability of real-world analysis.
Patients with PNH may become more active following ravulizumab therapy | image credit: sutadimages - stock.adobe.com
August 16th 2024

Ravulizumab Boosts Activity Levels, Quality of Life in Patients With PNH

Connor Iapoce
Ravulizumab therapy may enable patients with paroxysmal nocturnal hemoglobinuria (PNH) to comparable achieve activity levels and patient-reported outcomes to the US general population.
Guidelines folder | Image Credit: tashatuvango-stock.adobe.com
August 16th 2024

New Guidelines Clarify MDS Classification, Highlight Diagnostic Nuances

Gayle Turim Dickstein
Authors acknowledge that both the 2022 World Health Organization and International Consensus Classification myelodysplastic syndrome criteria sets have value, while sorting out their similarities and differences.
FDA approval | Image Credit: Tada Images - stock.adobe.com
August 15th 2024

FDA Approves Axatilimab-csfr for Chronic Graft-vs-Host Disease

Cameron Santoro
The FDA has approved axatilimab-csfr (Niktimvo) for treating adults and children with chronic graft-versus-host disease who have progressed on at least 2 prior treatments.
Anna Sureda, MD, PhD
August 10th 2024

Advancements in R/R Lymphoma: Bispecific Antibodies in Focus

Brooke McCormick Maggie L. Shaw
In part 1 of our interview with Anna Sureda, MD, PhD, president of the European Group for Blood and Marrow Transplantation, she summarized the current treatment landscape for relapsed/refractory diffuse large B-cell lymphoma (R/R DLBCL) and follicular lymphoma (FL).
Precision medicine | Image Credit: leowolfert-stock.adobe.com
August 8th 2024

Opportunities Remain for Expanding Precision Medicine in CLL

AJMC Contributor
As the treatment landscape for chronic lymphocytic leukemia (CLL) has moved into an era where targeted treatments are a mainstay of treatment, new opportunities to tailor therapy have emerged.
MM blood test | Image Credit: luchschenF-stock.adobe.com
August 6th 2024

Novel Therapies Needed for Older Patients With RRMM

Maggie L. Shaw
Relapsed/refractory multiple myeloma (RRMM) remains an incurable hematologic cancer, often resulting in patients treated with several classes of medications—particularly older patients.
Sickle cell retinopathy is a manifestation of SCD that occurs in the eye and can cause detriments to patients’ vision| image credit: Катерина Євтехова - stock.adobe.com
August 5th 2024

The Benefits of More Sickle Cell Retinopathy Screening for Patients With SCD

Kyle Munz
A systematic analysis that reviewed screening for sickle cell retinopathy in patients with sickle cell disease (SCD) underscores the importance of advanced imaging measures and further research on screening implementation methods.
doc comforting patient | Image Credit: Seventyfour-stock.adobe.com
August 3rd 2024

Blinatumomab Boosts Survival in MRD-Negative BCP-ALL

Jared Kaltwasser
Adding blinatumomab to consolidation chemotherapy for B-cell precursor acute lymphoblastic leukemia (BCP-ALL) in patients without measurable residual disease (MRD) led to improvements in overall and relapse-free survival.
MDS wooden blocks | Image Credit: Sviatlana - stock.adobe.com
August 2nd 2024

Report: ESAs Largely Ineffective in Lower-Risk MDS

Jared Kaltwasser
Only about a quarter of patients who have myelodysplastic syndrome (MDS) experienced hematologic improvement with erythropoiesis-stimulating agents (ESAs).
doc interviewing patient | Image Credit: ChasingMagic/peopleimages.com-stock.adobe.com
August 1st 2024

Accurately Capturing Experiences of Patients With NHL

Jared Kaltwasser
Investigators wanted to know how well the NFlymSI-18 assessment was able to assess patient-reported outcomes in people with indolent B-cell non-Hodgkin lymphoma (NHL).
FDA | Image Credit: ra2studio-stock.adobe.com
July 31st 2024

Daratumumab and Hyaluronidase-fihj–Based Quadruplet Regimen Approved in MM

Maggie L. Shaw
Daratumumab/hyaluronidase-fihj plus bortezomib, lenalidomide, and dexamethasone is now approved by the FDA to treat newly diagnosed multiple myeloma (MM) in patients eligible for autologous stem cell transplant.
awareness of hematologic disorders | Image Credit: Orawan-stock.adobe.com
July 30th 2024

ActivinA Helps B-ALL Cells by Inducing Extracellular Vesicles

Jared Kaltwasser
A new study suggests inhibiting ActivinA might improve the efficacy of chemotherapy in patients with B-cell acute lymphoblastic leukemia (B-ALL).
stem cell transplant | Image Credit: Vadim-stock.adobe.com.jpeg
July 28th 2024

HCT Outcomes Show Improvement With Posttransplant Cyclophosphamide

Karen Jacobson-Sive
Post–hematopoietic cell transplantation (HCT) prophylaxis using cyclophosphamide to stave off graft-vs-host disease had positive results compared with calcineurin inhibitor–based prophylaxis, regardless of whether the patient had a matched or unmatched donor.
Clinical link research | Image Credit: sdecoret - stock.adobe.com
July 27th 2024

MRD, Clinical Outcomes Linked in Chronic Leukemia

Gayle Turim Dickstein
This systematic review focusing on the targeted therapy era found solid associations between measurable residual disease (MRD) and clinical outcomes in patients with chronic lymphocytic leukemia.
pregnant woman who is too hot| Image Credit: Studio Romantic-stock.adobe.com
July 27th 2024

High Ambient Temperatures in Pregnancy Related to Childhood Leukemia Risk

Gayle Turim Dickstein
When the mercury outside ascends too high early in pregnancy, the risk of pediatric acute lymphoblastic leukemia may rise as well; results also show greater impacts on Latino populations.
CAR T in MM | Image Credit: LASZLO-stock.adobe.com
July 25th 2024

Dual-Target CAR T Cells Achieve 100% Response Rate in MM

Maggie L. Shaw
This new analysis examined the investigational chimeric antigen receptor (CAR) T-cell therapy GC012F among patients with newly diagnosed and high-risk multiple myeloma (MM).
Efanesoctocog alfa is a high-sustained factor VIII replacement therapy for the treatment of hemophilia A | image credit: Ekaterina - stock.adobe.com
July 25th 2024

Efanesoctocog Alfa Prophylaxis Promising for Pediatric Severe Hemophilia A

Kyle Munz
The phase 3, international, open-label, single-group XTEND-Kids study concluded that children with severe hemophilia A younger than 12 years benefited from treatment with efanesoctocog alfa prophylaxis.
A panel of 4 experts on PNH
July 24th 2024

Financial Considerations Influencing Treatment Strategies in PNH Treatment Pathway

Ryan Haumschild, PharmD, MS, MBA Jamie L. Koprivnikar, MD David Dingli, MD, PhD Brian P. Mulherin, MD
The panelists provide their final thoughts, highlighting financial considerations in PNH treatment.
A panel of 4 experts on PNH
July 24th 2024

Ensuring PNH Treatment Access and Adherence to Therapies

Ryan Haumschild, PharmD, MS, MBA Jamie L. Koprivnikar, MD David Dingli, MD, PhD Brian P. Mulherin, MD
Barriers to care and treatment adherence for patients diagnosed with PNH is discussed.
Ryan Jacobs, MD, Atrium Health Levine Cancer Institute
July 23rd 2024

Exploring the Efficacy and Safety of Ibrutinib and Venetoclax in CLL

Brooke McCormick Maggie L. Shaw
Ryan Jacobs, MD, lymphoma division director at Atrium Health Levine Cancer Institute, explains the design and objectives of the phase 2 CAPTIVATE study comparing ibrutinib and venetoclax in patients with chronic lymphocytic leukemia (CLL).
CAR T | Image Credit: Christoph Burgstedt-stock.adobe.com
July 23rd 2024

In LBCL, Barriers to CAR T Remain: SDOH and More

Gayle Turim Dickstein
The social determinants of health (SDOH) that need to be tackled most urgently when it comes to which patients with large B-cell lymphoma (LBCL) do and do not receive chimeric antigen receptor T-cell therapy (CAR T) are age, sex, income, and race/ethnicity.
acute leukemia | Image Credit: GoodIdeas-stock.adobe.com
July 22nd 2024

New Study Highlights Venetoclax Combo Efficacy in ALL

Kimberly Rath, PharmD
This new study evaluates the efficacy of monotherapies and venetoclax combination therapies in different T-cell acute lymphoblastic leukemia (ALL) cell lines.
MDS test | Image Credit: Saiful52-stock.adobe.com
July 22nd 2024

Study Identifies Risk Factors for Progression From Low-Risk MDS

Jared Kaltwasser
The findings show most patients with low-risk myelodysplastic syndrome (MDS) will die before progression.
cancer treatment | Image Credit: tashatuvango-stock.adobe.com
July 20th 2024

Study Reveals Top Treatment Priorities in Patients With CLL

Kimberly Rath, PharmD
Researchers of a new study explore what areas of chronic lymphocytic leukemia (CLL) treatment and care are important to patients and identify key areas for improvement.
Support group image | Image Credit: Tom Merton/KOTO-stock.adobe.com
July 17th 2024

Myeloma Survivorship Program: Findings and Future Steps

Maggie L. Shaw
Peer and survivorship support are lacking for patients living with multiple myeloma, leading investigators to evaluate a group-focused multidisciplinary intervention that encompassed physical and mental activities.
Brian Koffman, MDCM, DCFP, FCFP, DABFP, MSEd, CLL Society
July 16th 2024

Advancements in CLL: A Conversation With Dr Brian Koffman

Brooke McCormick Maggie L. Shaw
In this interview from our coverage of the European Hematology Association 2024 Congress, we spoke with Brian Koffman, MDCM, DCFP, FCFP, DABFP, MSEd, executive vice president and chief medical officer of the CLL Society and himself a survivor of chronic lymphocytic leukemia (CLL), to discuss treatment advancements and the importance of addressing both unmet needs and patient treatment preferences.
<12345678910
...
28>

2 Commerce Drive
Suite 100
Cranbury, NJ 08512

© 2025 MJH Life Sciences® and AJMC®.
All rights reserved.

About
Contact
Editorial Boards
Advertise
Do Not Sell My Information
Terms & Conditions
Privacy Policy
AJMC Managed Markets Network Logo
CH LogoCenter for Biosimilars Logo